{
  "docId": "019dd923-622c-750b-8b99-daa7bab7aec2",
  "docSlug": "f687a225f056",
  "documentTitle": "Enfusion, Inc. (ENFN)",
  "authorId": "54_Spruce_Point_Capital",
  "authorName": "Spruce Point Capital Management",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2024-03-14 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 28,
  "pageCount": 30,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "preempt_rebuttal",
  "function": "preempt_rebuttal",
  "density": "balanced",
  "nDataPoints": 18,
  "notes": "The slide uses a pie chart to visualize analyst sentiment distribution, highlighting a split between buy and sell ratings.",
  "elementsJson": [
    "headline_text",
    "callout_box",
    "data_table",
    "pie_chart",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b99-daa7bab7aec2/28",
  "deckHref": "/decks/019dd923-622c-750b-8b99-daa7bab7aec2",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b99-daa7bab7aec2.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b99-daa7bab7aec2#slide-28",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "The sell-side analyst community appears equally divided on ENFN's share price outlook. However, we believe the biggest bulls on the name are wrong in their assessments and have failed to conduct a rigorous forensic analysis of the Company's reporting.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-78b5-7512-b5b7-62811749a6fa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.41,
        "x": 0.56,
        "y": 0.38
      },
      "kind": "chart",
      "text": "Ratings Distribution pie chart showing 43% Buy, 14% Neutral, 43% Sell",
      "attrs": null,
      "subkind": "pie",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "319bda6f-fe64-4d08-be4a-f5a6afe8e712",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Average Price Target: $9.83",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-78b5-7512-b5b7-677ea4f37cea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.96,
        "x": 0.02,
        "y": 0.17
      },
      "kind": "paragraph",
      "text": "The sell-side analyst community appears equally divided on ENFN's share price outlook. However, we believe the biggest bulls on the name are wrong in their assessments and have failed to conduct a rigorous forensic analysis of the Company's reporting.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c72554a-5941-4482-8651-91946a451401",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.28,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Bloomberg and Spruce Point analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae38a16d-1ae1-40bd-9a27-afd390cb56b0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.63,
        "w": 0.51,
        "x": 0.03,
        "y": 0.285
      },
      "kind": "table",
      "text": "Analyst, Recommendation, Price Target table for Enfusion",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c0297075-70d5-48d0-8f85-e060d9701b34",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.65,
        "x": 0.31,
        "y": 0.04
      },
      "kind": "title",
      "text": "Poor Risk / Reward Owning Enfusion",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96ab2d9e-ea66-4598-b8ca-6625eea09820",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "ae86ce84-5cc1-4686-96fd-37759fe4d6b7",
      "evidence": "The sell-side analyst community appears equally divided on ENFN's share price outlook.",
      "confidence": 0.5
    },
    {
      "name": "Thesis archetype",
      "slug": "thesis-archetype",
      "agent": null,
      "layer": "slide",
      "matchId": "3a6a4f82-fe71-4b4e-aefe-66e6352b37f2",
      "evidence": "The sell-side analyst community appears equally divided on ENFN's share price outlook. However, we believe the biggest bulls on the name are wrong in their assessments and have failed to conduct a rigorous foren",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 23,
      "beatId": "5d837ca3-3b2c-4012-bccf-1779a590d5de",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "Preempt Rebuttal",
      "beatSlug": null,
      "evidence": "Spruce Point preempts potential rebuttals to its analysis",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 28,
      "from": 22,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "0e49f9c0-3ee3-452c-bf97-4682f1fb7335",
      "evidence": "The document highlights the potential cost of inaction for investors who fail to act on Enfusion's concerns",
      "position": 2,
      "objective": "What is the cost of inaction for investors who fail to act on Enfusion's concerns?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}